OncoMatch/Clinical Trials/NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Is NCT06484920 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including ATRA and Pembrolizumab for relapsed hodgkin lymphoma.
Treatment: ATRA · Pembrolizumab — This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy — relapsed HL: at least 1 prior line; PMBCL: refractory to first-line; other B-cell NHLs: at least 2 prior lines
HL after failure of at least 1 prior line of systemic therapy; PMBCL that is refractory to first-line therapy; Other B-cell NHLs after failure of at least 2 prior lines of systemic therapy
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Cannot have received: anti-cancer monoclonal antibody
Exception: within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier
Cannot have received: chemotherapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Cannot have received: targeted small molecule therapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Cannot have received: radiation therapy
Exception: within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1,500 /mcL; Platelets ≥100,000 / mcL; Hemoglobin ≥9 g/dL or ≥5.6 mmol/L without transfusion or EPO dependency (within 7 days of assessment); INR and aPTT ≤1.5 x ULN (applies only to patients not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose)
Kidney function
calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) calculated creatinine clearance ≥ 60 mL/min
Liver function
Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN (patients with known Gilbert disease who have bilirubin levels ≤ 3 x ULN may be enrolled). AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR 5 X ULN for subjects with liver metastases. Albumin >2.5 mg/dL.
Adequate hematologic and end organ function, defined by the following laboratory results obtained within 10 days prior to the first study treatment: ... (see above for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center · Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital · Indianapolis, Indiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06484920 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, anti-cancer monoclonal antibody, chemotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages